FilingReader Intelligence
Pharmaron boosts overseas investment by $10.5m
August 21, 2025 at 05:24 PM UTC•By FilingReader AI
Pharmaron Beijing is investing an additional $10.5 million in PharmaGend Global Medical Services, raising its total investment to $38.5 million.
The company is also adjusting multiple share incentive plans from 2021-2023, cancelling 634,880 restricted shares due to employee departures and unmet performance targets.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2025 semi-annual reportAugust 21, 2025 at 08:00 AM UTC
Summary table of non-operating fund occupation and other related party fund transactions for the first half of 2025August 21, 2025 at 08:00 AM UTC
Announcement on the invalidation and forfeiture of certain granted but unvested restricted shares under the 2021, 2022, and 2023 A-share restricted stock incentive plansAugust 21, 2025 at 08:00 AM UTC
Announcement on the achievement of vesting conditions for the third vesting period of the 2022 A-share restricted stock incentive plan, but with the shares temporarily not listedAugust 21, 2025 at 08:00 AM UTC
Announcement regarding the fulfillment of vesting conditions for the fourth vesting period of the 2021 A-share restricted stock incentive plan, but with temporary non-listing of the sharesAugust 21, 2025 at 08:00 AM UTC
Announcement regarding the adjustment of matters related to the 2021, 2022, and 2023 A-share restricted stock incentive plansAugust 21, 2025 at 08:00 AM UTC
2025 semi-annual report summaryAugust 21, 2025 at 08:00 AM UTC
Independent financial advisor report of Shanghai Miaodao Enterprise Management Consulting Co., Ltd. regarding the achievement of vesting conditions for the third vesting period of the company's 2022 A-share restricted stock incentive planAugust 21, 2025 at 08:00 AM UTC
Independent financial advisor report of Shanghai Miaodao enterprise management consulting Co., Ltd. concerning the achievement of vesting conditions for the fourth vesting period of the company's 2021 A-share restricted stock incentive planAugust 21, 2025 at 08:00 AM UTC
Legal opinion from Beijing Zhonglun Law Firm regarding the adjustment of the grant price and the cancellation of some restricted shares under the company's 2023 A-share restricted stock incentive planAugust 21, 2025 at 08:00 AM UTC
Legal opinion from Beijing Zhong Lun Law Firm regarding the adjustment of the grant price for the company's 2022 A-share restricted stock incentive plan, the fulfillment of vesting conditions for the third vesting period but temporary non-listing of shares, and the invalidation of certain restricted shares.August 21, 2025 at 08:00 AM UTC
Legal opinion from Beijing Zhong Lun Law Firm regarding the company's 2021 A-share restricted stock incentive plan share grant price adjustment, the achievement of vesting conditions for the fourth vesting period but temporary non-listing of shares, and the cancellation of certain restricted sharesAugust 21, 2025 at 08:00 AM UTC
SZSE:300759•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Pharmaron Beijing publishes news
Free account required • Unsubscribe anytime